trial

Zyprexa® Relprevv™ Patient Care Program

NCTId NCT01088386
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Enrolling By Invitation
Enrollment 4,000 (estimated)
Sponsored by Eli Lilly and Company
Primary completion 2026-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Enrolling By Invitation
Enrollment
4,000 (estimated)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2010-03-03
Primary completion
2026-06
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
—

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

1 total
Blue Bell, United States

Facts & assertions

4 sourced
Enrollment
4,000
Phase
NA
Primary Completion Date
2026-06
Status
ENROLLING_BY_INVITATION
relationships
The graph out of here
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person